Some stock data isn't available right now.
Gilead Sciences Inc (GILD)
Underlying price
$159.02+3.57% today
Stock stats
- Market cap
- $190B
- Previous close
- $153.54
- Open
- $156.39
- Day's range
- $156.02 – $160.51
- 52-week range
- $114.02 – $157.29
- Volume
- 3.23M
- Avg volume
- 5.64M
- P/E ratio
- -
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Ticker
- GILD
- Asset class
- Equity
- Tokenized by
- 0 issuers
- Sector
- Healthcare
- Industry
- Biological Products, (no Diagnostic Substances)
- Employees
- 17,000
- Website
- gilead.com